CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis

NeuroImmunoModulation

Volumn 18, Issue 1, 2010, Pages 67-72

  Szczuciński, Adam ^a   Losy, Jacek ^a,b,c  

^a Szpital Kliniczny Im H Śǐcickiego Uniwersytetu Medycznego W Poznaniu ^*  (Poland)

^b University of Medical Sciences   (Poland)

^c POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

CCL5; Chemokines; CXCL10; CXCL11; Methylprednisolone; Multiple sclerosis

Indexed keywords

CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; RANTES;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; TENSION HEADACHE;

ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS; CHEMOKINE CCL5; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOKINES; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; UP-REGULATION; YOUNG ADULT;

EID: 77955603960     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317394     Document Type: Article

References (29)

1. Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in Immunity. Immunity 2000; 12:121-127.
2. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in in-flammation. N Engl J Med 2006; 354: 610-621.
3. Szczucinski A, Losy J: Chemokines and che-mokine receptors in multiple sclerosis. Po-tential targets for new therapies. Acta Neurol Scand 2007; 115:137-146.
4. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN: Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflamma-tory cells in multiple sclerosis lesions. J Neu-roimmunol 1998; 84:238-249.
5. Sørensen TL, Tani M, Jensen J, Pierce V, Luc-chinetti C, Folcik VA, Qin S, Rottman J, Sel-lebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM: Expression of specific che-mokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103:807-815.
6. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V: Se-rum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immuno-mudulatory therapies. J Neuroimmunol 2001; 115: 192-198.
7. Bartosik-Psujek H, Stelmasiak Z: The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005; 12: 49-54.
8. Scarpini E, Galimberti D, Baron P, Clerici R Ronzoni M, Conti G, Scarlato G: IP-10 and MCP-1 levels in CSF and serum from multi-ple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci 2002; 195: 41-46.
9. Mahad DJ, Howell SJL, Woodroofe MN: Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72:498-502.
10. Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark-Lewis I: The ligands of CXC chemokine re-ceptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001; 276: 2986-2991.
11. Bartosik-Psujek H, Stelmasiak Z: Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis pa-tients during relapse. Eur Neurol 2004; 52: 237-241.
12. McDonald WI, Compston A, Edan G, Good-kin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolin-sky JS: Recommended diagnostic criteria for multiple sclerosis: guidelines from the Inter-national Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-127.
13. Johnson Z, Schwarz M, Power CA, Wells TNC, Proudfoot AEI: Multi-faceted strate-gies to combat disease by interference with the chemokine system. Trends Immunol 2005; 26: 268-274.
14. Terricabras E, Benjamim C, Godessart N: Drug discovery and chemokine receptor an-tagonists: eppur si muove! Autoimmun Rev 2004; 3:550-556.
15. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN: Expression of the interfer-on-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neuro-biol 2000; 26: 133-142.
16. Sindern E, Patzold T, Ossege LM, Gisevius A, Malin JP: Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is re-lated to active MRI lesion appearance in pa-tients with relapsing-remitting multiple scle-rosis. J Neuroimmunol 2002; 131: 186-190.
17. Xie JH, Nomura N, Lu M, Chen SL, Koch GE, Weng Y, Rosa R, Di Salvo J, Mudgett J, Peter-son LB, Wicker LS, De Martino JA: Anti-body-mediated blockade of the CXCR3 che-mokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol 2003; 73: 771-780.
18. Teleshova N, Pashenkov M, Huang YM, Sod-erström M, Kivisäkk P, Kostulas V, Haglund M, Link H: Multiple sclerosis and optic neu-ritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J Neurol 2002; 249:723-729.
19. Lepej SZ, Rode OD, Jeren T, Vince A, Reme-nar A, Barsic B: Increased expression of CXCR3 and CCR5 on memory CD4+ T-cells migrating into the cerebrospinal fluid of pa-tients with neuroborreliosis: the role of CXCL10 and CXCL11. J Neuroimmunol 2005; 163:128-134.
20. Lepej SZ, Misic-Majerus L, Jeren T, Rode OD, Remenar A, Sporec V, Vince A: Chemo-kines CXCL10 and CXCL11 in the cerebro-spinal fluid of patients with tick-borne en-cephalitis. Acta Neurol Scand 2007; 115: 109-114.
21. Nureki SI, Miyazaki E, Ando M, Ueno T, Fu-kami T, Kumamoto T, Sugisaki K, Tsuda T: Circulating levels of both Th1 and Th2 che-mokines are elevated in patients with sar-coidosis. Respir Med 2008; 102: 239-247.
22. Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT: Expression of the chemokine re-ceptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive as-trocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 2000; 108:227-235.
23. Hvas J, McLean C, Justesen J, Kannourakis G, Steinman L, Oksenberg JR, Bernard CC: Perivascular T cells express the pro-inflam-matory chemokine RANTES mRNA in mul-tiple sclerosis lesions. Scand J Immunol 1997; 46: 195-203.
24. Trebst C, Sørensen TL, Kivisäkk P, Cathcart MK, Hesselgesser J, Horuk R, Sellebjerg F, Lassmann H, Ransohoff RM: CCR1+/ CCR5+ mononuclear phagocytes accumu-late in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001; 159:1701-1710.
25. Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C: Natalizumab treat-ment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 2010; 16:208-217.
26. Sloka JS, Stefanelli M: The mechanism of ac-tion of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005; 11: 425-432.
27. Sørensen TL, Sellebjerg F, Jensen CV, Strieter RM, Ransohoff RM: Chemokines CXCL10 and CCL2: differential involvement in intra-thecal inflammation in multiple sclerosis. Eur J Neurol 2001; 8:665-672.
28. Moreira MA, Tilbery CP, Monteiro LP, Teix-eira MM, Teixeira AL: Effect of the treatment with methylprednisolone on the cerebrospi-nal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand 2006; 114:109-113.
29. Michałowska-Wender G, Losy J, Szczucinski A, Biernacka- Łukanty J, Wender M: Effect of methylprednisolone treatment on expres-sion of sPECAM-1 and CXCL10 chemokine in serum of MS patients. Pharmacol Rep 2006; 58: 920-923.